Search Result

Results for "

MK2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MAPKAPK2 (MK2) (13) Apoptosis (1) Autophagy (5) ERK (2) HSP (4) JNK (2) p38 MAPK (10)
By Research Areas:	Cancer (8) Inflammation/Immunology (15) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Targets Recommended: MAPKAPK2 (MK2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10072A

MK2-IN-5 acetate Hsp25 kinase inhibitor acetate; MK2 pseudosubstrate acetate	JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK	Others
MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation .

HY-12834A

MK2-IN-1 hydrochloride 3 Publications Verification	MAPKAPK2 (MK2) HSP	Cancer
MK2-IN-1 hydrochloride (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 0.11 uM for MK2 and an EC₅₀ of 0.35 uM for pHSP27. MK2-IN-1 hydrochloride impaires the phosphorylation level of serine residues in the Tfcp2l1 protein .

HY-131249

MK2-IN-3 2 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC₅₀ of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC₅₀s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC₅₀s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .

HY-112457

MK2-IN-3 hydrate 2 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC₅₀ of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC₅₀=0.21 μM), MK-5 (IC₅₀=0.081 μM), ERK2 (IC₅₀=3.44 μM), MNK1(IC₅₀=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .

HY-108643

CMPD1	MAPKAPK2 (MK2)	Cancer
CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent K_i (K_i ^app) of 330?nM .

HY-139553

Zunsemetinib ATI-450; CDD-450	MAPKAPK2 (MK2)	Inflammation/Immunology
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-P10072

MK2-IN-5 Hsp25 kinase inhibitor; MK2 pseudosubstrate	ERK JNK p38 MAPK HSP MAPKAPK2 (MK2)	Others
MK2-IN-5 is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation .

HY-162700

MK2-IN-6	MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
MK2-IN-6 (Compound 11) is a potent and selective irreversible MK2 inhibitor with an IC₅₀ value of 2.3 nM. MK2-IN-6 inhibits MK2 kinase activity, achieving prolonged MK2 signaling suppression and reducing pathological inflammatory cytokines in macrophages. MK2-IN-6 inhibits the M2-like protumor phenotype of macrophages both in vitro and in vivo, which is proming for research of colorectal cancer .

HY-147283

MK2-IN-4	MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor with an IC₅₀ value of 45 nM. MK2-IN-4 can be used in the research of cancer, inflammation, immunology .

HY-12834

MK2-IN-1	MAPKAPK2 (MK2) HSP	Cancer
MK2-IN-1 (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 0.11 uM for MK2 and an EC₅₀ of 0.35 uM for pHSP27. MK2-IN-1 impaires the phosphorylation level of serine residues in the Tfcp2l1 protein .

HY-120111

MW-150 MW01-18-150SRM	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-139553A

(R)-Zunsemetinib (R)-ATI-450; (R)-CDD-450	Others	Inflammation/Immunology
(R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-151921

Anti-inflammatory agent 33	p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 33 is a potent p38α inhibitor. Anti-inflammatory agent 33 inhibits NO production. Anti-inflammatory agent 33 inhibits LPS-induced iNOS, COX-2, p-p38α, p-MK2 protein expression. Anti-inflammatory agent 33 shows anti-inflammatory activity .

HY-139504

Gamcemetinib CC-99677	MAPKAPK2 (MK2)	Inflammation/Immunology
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC₅₀=156.3 nM) and cell based assays (EC₅₀=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .

HY-120111A

MW-150 hydrochloride MW01-18-150SRM hydrochloride	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-13241

Ralimetinib dimesylate Maximum Cited Publications 12 Publications Verification LY2228820 dimesylate	p38 MAPK Autophagy Apoptosis	Inflammation/Immunology Cancer
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-107427

PF-3644022 1 Publications Verification	MAPKAPK2 (MK2) p38 MAPK	Inflammation/Immunology
PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 5.2 nM and a K_i of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC₅₀s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect .

HY-120111B

MW-150 dihydrochloride dihydrate MW01-18-150SRM dihydrochloride dihydrate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-13241A

Ralimetinib LY2228820	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc .

HY-P3412

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

HY-150612

(R)-STU104	p38 MAPK	Cancer
(R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC₅₀s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis .

Cat. No.	Product Name	Target	Research Area

HY-P10072A

MK2-IN-5 acetate Hsp25 kinase inhibitor acetate; MK2 pseudosubstrate acetate	JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK	Others
MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation .

HY-P3412

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

HY-P10072

MK2-IN-5 Hsp25 kinase inhibitor; MK2 pseudosubstrate	ERK JNK p38 MAPK HSP MAPKAPK2 (MK2)	Others
MK2-IN-5 is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.